Progestogens: Effects on clinical and biochemical parameters in postmenopausal women

Menopause

Volumn 12, Issue 5, 2005, Pages 484-487

  Archer, David F ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; DYDROGESTERONE; ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE; PROGESTERONE; PROGESTERONE RECEPTOR; THROMBOSPONDIN 1; VASCULOTROPIN;

AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; EDITORIAL; ENDOMETRIUM HYPERPLASIA; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; UTERUS BLEEDING;

ADMINISTRATION, CUTANEOUS; AMENORRHEA; CONTRACEPTIVE AGENTS, FEMALE; DYDROGESTERONE; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MEGESTROL; NORPREGNADIENES; POSTMENOPAUSE; PROGESTERONE; UTERINE HEMORRHAGE;

EID: 25444487458     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000177319.31629.52     Document Type: Editorial

References (51)

1. Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001;8:245-251.
2. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994;83:686-692.
3. Dickey RP, Stone SC. Progestational potency of oral contraceptives. Obstet Gynecol 1976;47:106-112.
4. Moyer DL, Felix JC. The effects of progesterone and progestins on endometrial proliferation. Contraception 1998;57:399-403.
5. Sturdee DW. Endometrial morphology and bleeding patterns as a function of progestogen supplementation. Int J Fertil Menopausal Stud 1996;41:22-28.
6. DiCarlo C, Sammartino A, DiSpiezio Sardo A, et al. Bleeding patterns during continuous estradiol with different sequential progestogens therapy. Menopause 2005;12:520-525.
7. Scott RT, Jr, et al. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991;77:758-764.
8. Stanczyk FZ. All progestins are not created equal. Steroids 2003;68:879-890.
9. Archer DF, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-1087.
10. Lindenfeld EA, Langer RD. Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. Obstet Gynecol 2002;100:853-863.
11. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995;86:306-316.
12. Archer DF, et al. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group. Obstet Gynecol 1999;94:323-329.
13. Grubb G, et al. Clinical experience with trimegestone as a new progestin in HRT. Steroids 2003;68:921-926.
14. Whitehead MI, et al. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599-1605.
15. Ryder TA, Mobberley MA, Whitehead MI. The endometrial nucleolar channel system as an indicator of progestin potency in HRT. Maturitas 1995;22:31-36.
16. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002;9:6-15.
17. Pickar JH, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;76:25-31.
18. Kendall BS, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998;22:1012-1019.
19. Lundeen SG, et al. Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone. J Steroid Biochem Mol Biol 2001;78:137-143.
20. Sayegh RA, et al. Localization of the expression of complement component 3 in the human endometrium by in situ hybridization. J Clin Endocrinol Metab 1996;81:1641-1649.
21. Bischof P, et al. Investigations on the cell type responsible for the endometrial secretion of complement component 3 (C3). Hum Reprod 1994;9:1652-1659.
22. Young SL, et al. In vivo and in vitro evidence suggest that HB-EGF regulates endometrial expression of human decay-accelerating factor. J Clin Endocrinol Metab 2002;87:1368-1375.
23. Wallach EE. Physiology of menstruation. Clin Obstet Cynecol 1970;13:366-385.
24. Hickey M, d'Arcangues C. Mechanisms underlying menstrual bleeding disturbances with progestogens. Ernst Schering Res Found Workshop 2005;52:191-217.
25. Hickey M, et al. Changes in endometrial blood vessels in the endometrium of women with hormone replacement therapy-related irregular bleeding. Hum Reprod 2003;18:1100-1106.
26. Belsey EM, Pinol AP. Menstrual bleeding patterns in untreated women. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception 1997;55:57-65.
27. Lober J, et al. Pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular route. Acta Obstet Cynecol Scand Suppl 1981;101:71-74.
28. de Bree H, et al. Dydrogesterone: metabolism in animals. Eur J Drug Metab Pharmacokinet 1983;8:63-67.
29. van Amsterdam PH, et al. Dydrogesterone: metabolism in man. Eur J Drug Metab Pharmacokinet 1980;5:173-184.
30. van de Weijer PH, et al. Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy. Obstet Cynecol 1999;93:551-557.
31. Ezan E, et al. Enzyme immunoassay for nomegestrol acetate in human plasma. J Steroid Biochem Mol Biol 1993;46:507-514.
32. Cornet PB, et al. Regulation of matrix metalloproteinase-9/gelatinase B expression and activation by ovarian steroids and LEFTY-A/endometrial bleeding-associated factor in the human endometrium. J Clin Endocrinol Metab 2005;90:1001-1011.
33. Zhang J, et al. Progesterone inhibits activation of latent matrix metalloproteinase (MMP)-2 by membrane-type 1 MMP: enzymes coordinately expressed in human endometrium. Biol Reprod 2000;62:85-94.
34. Archer DF, et al. Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, and 17beta-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cells. Fertil Steril 2004;81:165-170.
35. Mirkin S, Archer DF. Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, progesterone, and 17beta-estradiol on thrombospondin-1 mRNA in Ishikawa cells. Fertil Steril 2004;82:220-222.
36. Mirkin S, Navarro F, Archer DF. Hormone therapy and endometrial angiogenesis. Climacteric 2003;6:273-277.
37. Archer DF, et al. A comparative study of transvaginal uterine ultrasound and endometrial biopsy for evaluating the endometrium of postmenopausal women taking hormone replacement therapy. Menopause 1999;6:201-208.
38. Holbert TR. Transvaginal ultrasonographic measurement of endometrial thickness in postmenopausal women receiving estrogen replacement therapy. Am J Obstet Cynecol 1997;176:1334-1339.
39. Pickar JH, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003;80:1234-1240.
40. Ferenczy A, et al. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone. Climacteric 2002;5:26-35.
41. Kurman RJ, et al. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Cynecol 2000;96:373-379.
42. Moyer DL, et al. Micronized progesterone regulation of the endometrial glandular cycling pool. Int J Gynecol Pathol 2001;20:374-379.
43. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208.
44. de Kraker AT, et al. The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a). Maturitas 2004;49:253-263.
45. Lobo RA, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001;76:13-24.
46. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915.
47. Al-Azzawi F, et al. Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women. Climacteric 2004;7:292-300.
48. Odmark IS, et al. Long-term effects of two different continuous combined regimens of hormone replacement therapy on well-being. Gynecol Endocrinol 2004;18:305-317.
49. Sherwin BB. Progestogens used in menopause. Side effects, mood and quality of life. J Reprod Med 1999;44(2 Suppl):227-232.
50. Chwalisz K, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-438.
51. Winnower RC, et al. Nonsteroidal progesterone receptor modulators: structure activity relationships. Semin Reprod Med 2005;23:46-57.